Brazil Pharma and Healthcare Sector Report 2023-2024

Brazil's pharmaceutical and healthcare sector encountered problems during the COVID-19 pandemic, including shortages of drugs and active pharmaceutical ingredients (APIs), rapid price increases for pharmaceutical products and strained finances in the private health insurance system. Nonetheless, the sector was able to tackle these challenges with a sharp rise in public health spending in 2020-2021 and by adjustments in the private sector that were geared towards improving profitability, such as the vertical integration of private health insurers with private health centre operators. In the post pandemic period, the sector will have to adjust to a decrease in public health spending due to budget restrictions, mostly at the federal level, and will continue to battle with chronic issues, such as a poor geographical distribution of the medical workforce. The domestic pharmaceutical manufacturing segment, although quite developed for Latin American standards, is broadly specialised in generics and cannot compete with foreign players for high cost drugs, leading to increasingly large external trade imbalances in pharmaceuticals.

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for Brazil. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in Brazil
• Crystallise the forces both driving and restraining this sector in Brazil
• Ascertain Brazil’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Brazil.
• Build a clear picture of trends, output and consumption for specific sub-sectors